Brief: Aligos Therapeutics Announces Clinical Collaboration With Xiamen Amoytop Biotech
22/07/2024 14:18
July 22 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS ANNOUNCES CLINICAL COLLABORATION WITH
XIAMEN
AMOYTOP BIOTECH CO., LTD.
* ALIGOS THERAPEUTICS: AMOYTOP TO SPONSOR, PERFORM PHASE 1B
STUDY
EVALUATING EFFICACY, SAFETY OF ALG-000184 IN COMBINATION WITH
PEGBING
* ALIGOS THERAPEUTICS INC: CLINICAL STUDY IS EXPECTED TO
BEGIN
AFTER APPROVAL BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION IN
CHINA
Source text for Eikon: ID:nGNX7M8SV1
Further company coverage: ALGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue